110 related articles for article (PubMed ID: 24299930)
1. Is dexamethasone associated with recurrence of ovarian cancer?
De Oliveira GS; McCarthy R; Turan A; Schink JC; Fitzgerald PC; Sessler DI
Anesth Analg; 2014 Jun; 118(6):1213-8. PubMed ID: 24299930
[TBL] [Abstract][Full Text] [Related]
2. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer.
De Oliveira GS; Schink JC; Buoy C; Ahmad S; Fitzgerald PC; McCarthy RJ
Transfus Med; 2012 Apr; 22(2):97-103. PubMed ID: 22151920
[TBL] [Abstract][Full Text] [Related]
3. Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer.
Merk BA; Havrilesky LJ; Ehrisman JA; Broadwater G; Habib AS
Curr Med Res Opin; 2016; 32(3):453-8. PubMed ID: 26583436
[TBL] [Abstract][Full Text] [Related]
4. Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study.
Kim MH; Kim DW; Park S; Kim JH; Lee KY; Hwang J; Yoo YC
BMC Cancer; 2019 Mar; 19(1):251. PubMed ID: 30894164
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
7. Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer.
Yu HC; Luo YX; Peng H; Kang L; Huang MJ; Wang JP
Eur J Surg Oncol; 2015 May; 41(5):667-73. PubMed ID: 25744813
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery.
de Oliveira GS; Ahmad S; Schink JC; Singh DK; Fitzgerald PC; McCarthy RJ
Reg Anesth Pain Med; 2011; 36(3):271-7. PubMed ID: 21519312
[TBL] [Abstract][Full Text] [Related]
9. Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer.
Matsuo K; Carter CM; Ahn EH; Prather CP; Eno ML; Im DD; Rosenshein NB
Am J Clin Oncol; 2013 Aug; 36(4):362-7. PubMed ID: 22643565
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
11. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
12. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
13. The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population.
Lacassie HJ; Cartagena J; Brañes J; Assel M; Echevarría GC
Anesth Analg; 2013 Sep; 117(3):653-660. PubMed ID: 23868889
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
15. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
[TBL] [Abstract][Full Text] [Related]
16. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
18. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
[TBL] [Abstract][Full Text] [Related]
20. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
